## ARUP LABORATORIES | aruplab.com

500 Chipeta Way, Salt Lake City, Utah 84108-1221 phone: 801-583-2787, toll free: 800-522-2787 Tracy I. George, MD, Chief Medical Officer

Patient Age/Sex: 1 day Male

Specimen	Collected:	08-Nov-21	09:29
----------	------------	-----------	-------

MEN1 by NGS, DelDup	Received:	09-Nov-21 09:41	Report/Verified: 09-Nov-21 09:47
Procedure	Result	Units	Reference Interval
MEN1 Specimen	Whole Blood		
MEN1 Interp	See Note <sup>i1</sup>		
Test Information			

il: MEN1 Interp

BACKGROUND INFORMATION: Multiple Endocrine Neoplasia Type 1 (MEN1) Sequencing and Deletion/Duplication

CHARACTERISTICS: Multiple endocrine neoplasia type 1 (MEN1) syndrome can include multiple endocrine and nonendocrine tumors. Common MEN1-related endocrine tumors include parathyroid, pancreatic islets, and pituitary. Nonendocrine tumors include facial angiofibroma, collagenoma, lipoma, meningioma, ependymoma, and leiomyoma. Primary hyperparathyroidism is the most common and often the first manifestation of MEN1. High mortality rates occur in individuals with gastrinoma and carcinoid tumors.

EPIDEMIOLOGY: 1/10,000 to 1/100,000.

CAUSE: Pathogenic germline variants in the MEN1 gene.

INHERITANCE: Autosomal dominant.

PENETRANCE: Greater than 50 percent by age 20 and 95 percent by age 40.

CLINICAL SENSITIVITY: A pathogenic MEN1 variant is identified in 80 to 90 percent of individuals who meet clinical criteria for MEN1 syndrome and have a family history of related cancers.

GENE TESTED: MEN1 (NM\_130799)

METHODOLOGY: Probe hybridization-based capture of all coding exons and exon-intron junctions of the targeted gene followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and to confirm reported variants that do not meet acceptable quality metrics. A proprietary bioinformatic algorithm was used to detect large (single exon level or larger) deletions or duplications in the indicated genes. Large deletions/duplications confirmed using an orthogonal exon-level microarray. Human genome build 19 (Hg 19) was used for data analysis.

ANALYTICAL SENSITIVITY/SPECIFICITY: The analytical sensitivity is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions (indels) from 1-10 base pairs in size. Indels

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at: ARUP Laboratories 500 Chipeta Way, Salt Lake City, UT 84108 Laboratory Director: Tracy I. George, MD

Patient Age/Sex: 1 day Male

## Test Information

## il: MEN1 Interp

greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced. Deletions of two exons or larger are detected with sensitivity greater than 97 percent; single exon deletions are detected with 62 percent sensitivity. Duplications of three exons or larger are detected at greater than 83 percent sensitivity. Specificity is greater than 99.9 percent for all variant classes.

LIMITATIONS: A negative result does not exclude a diagnosis of MEN1. A negative result does not exclude all genetic diagnoses. This test only detects variants within the coding regions and intron-exon boundaries of the MEN1 gene. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Regulatory region variants and deep intronic variants will not be identified. Precise breakpoints for large deletions or duplications are not determined in this assay and single exon deletions/duplications may not be detected based on the breakpoints of the rearrangement. The actual breakpoints for the deletion or duplication may extend beyond or be within the exon(s) reported. This test is not intended to detect duplications of two or fewer exons in size, though these may be identified. Single exon deletions are reported but called at a lower sensitivity. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations caused by the presence of pseudogenes, repetitive, or homologous regions. This test is not intended to detect low-level mosaic or somatic variants, gene conversion events, complex inversions, translocations, mitochondrial DNA (mtDNA) mutations, or repeat expansions. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Noncoding transcripts were not analyzed.

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at: ARUP Laboratories 500 Chipeta Way, Salt Lake City, UT 84108 Laboratory Director: Tracy I. George, MD 
 ARUP Accession:
 n/a

 Report Request ID:
 15064329

 Printed:
 13-Dec-21 10:54

 Page 2 of 2